Phase 3 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with multiple myeloma (a type of blood cancer) who have been recommended for a stem cell transplant using their own stem cells
- People whose pre-transplant treatment plan includes a chemotherapy drug called melphalan at a specific dose (200 mg/m²)
- People whose general health and activity level falls within a certain range, rated 0 to 2 on a standard medical scale (confirm with trial site)
- People aged between 18 and 64 years old
- People whose doctors expect them to survive for more than 3 months
- People who do not have raised pressure in the brain, a blockage in the digestive system, or other conditions causing severe, hard-to-treat vomiting
- People who are able to understand the trial and sign a written consent form
Who may not be able to join:
- People who experienced nausea or vomiting in the 48 hours before joining the trial, or who used anti-nausea medications during that time
- People who are currently taking, or have taken within the past month, certain medications that interact with a specific liver enzyme pathway called CYP3A4 (confirm with trial site for specific medications)
- People who have had an allergic reaction to either of the medications being studied: fosaprepitant or olanzapine
- People whose kidneys are not filtering blood efficiently enough, based on a standard kidney function measurement (below 60 mL/min)
- People who are unable to attend appointments at the trial site, or who are unable to understand and follow the trial instructions or provide written consent
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Peipei Ye, The Affiliated People's Hospital of Ningbo University
Phone: 86-13685832706
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Complete Response (CR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.